PRESS RELEASE published on 05/18/2023 at 23:15, 1 year 10 months ago Brigadier Announces First Closing of Private Placement
PRESS RELEASE published on 04/24/2023 at 15:00, 1 year 11 months ago Brigadier Appoints Geoffrey Gold as Special Advisor
PRESS RELEASE published on 04/13/2023 at 15:00, 1 year 11 months ago Brigadier Readies for Exploration at Nemaska2 Lithium Property
PRESS RELEASE published on 04/04/2023 at 15:00, 2 years ago Brigadier Appoints McGuinty Senior Technical Advisor
PRESS RELEASE published on 03/27/2023 at 15:00, 2 years ago Brigadier Engages Local Expertise for Lithium Exploration Programs
PRESS RELEASE published on 03/22/2023 at 14:00, 2 years ago Brigadier More Than Doubles the Size of its Nemaska2 Quebec Lithium Project
PRESS RELEASE published on 03/17/2023 at 14:00, 2 years ago Brigadier's NEMASKA2 Property Situated at Hub of James Bay Lithium Exploration Boom
PRESS RELEASE published on 03/14/2023 at 14:00, 2 years ago Brigadier Announces Completion of Nemaska2 Lithium Property Acquisition
PRESS RELEASE published on 02/17/2023 at 15:00, 2 years 1 month ago Brigadier Announces Receipt of TSX Conditional Approval for Acquisition of Quebec Lithium Interests
PRESS RELEASE published on 01/25/2023 at 15:00, 2 years 2 months ago Brigadier Provides Update on NEMASKA2 Lithium Project Transaction
Published on 04/09/2025 at 14:30, 10 minutes ago Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Published on 04/09/2025 at 14:15, 25 minutes ago Revolve Corporate Update Highlights Several Key Milestones
Published on 04/09/2025 at 14:00, 40 minutes ago Bausch Health, Canada Inc. et l’Alliance pharmaceutique pancanadienne signent une lettre d’intention concernant pour la couverture par les régimes publics d’assurance médicaments du traitement pour l’acné vulgaire (Pr)CABTREO(MC) (gel de phosph
Published on 04/09/2025 at 14:00, 40 minutes ago Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
Published on 04/09/2025 at 13:45, 55 minutes ago Quartz Commences Drilling at Prodigy High Grade Precious Metals Discovery on Its Maestro Property in British Columbia
Published on 04/09/2025 at 14:10, 30 minutes ago Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Published on 04/09/2025 at 11:26, 3 hours 14 minutes ago EQS-Adhoc: fox e-mobility AG: Resumption of trading – No challenge to capital resolutions – Legal remedy against the opening of bankruptcy proceedings at the Swiss subsidiary -
Published on 04/09/2025 at 11:24, 3 hours 16 minutes ago Electricité de Strasbourg - Avis de réunion AGO du 14 mai 2025 publié au BALO
Published on 04/09/2025 at 09:00, 5 hours 40 minutes ago STEF : Avis de mise à disposition des comptes annuels 2024
Published on 04/09/2025 at 08:00, 6 hours 40 minutes ago Museum Studio becomes a majority shareholder in Lord Cultural Resources
Published on 04/09/2025 at 08:00, 6 hours 40 minutes ago Museum Studio devient actionnaire majoritaire de Lord Cultural Resources
Published on 04/09/2025 at 07:00, 7 hours 40 minutes ago Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obésité